BioMarin’s Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels … – Stockhouse
|
BioMarin’s Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels …
Stockhouse BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today an update to its previously reported interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. The updated results will be … |
|
BioMarin’s Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels …
PR Newswire (press release) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. The updated results will … |
|
Regenerating the Body With Stem Cells – Hype or Hope?
Labiotech.eu (blog) When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in regenerative medicine. But 10 years after their … Stem Cell Banking Market To Grow at a CAGR of +18% by 2021 According to new researchMedgadget (blog) |
|
UPDATE 1-FDA panel to focus on safety of Novartis gene therapy …
Business Insider July 10 (Reuters) – The U.S. Food and Drug Administration will ask a panel of advisors to focus on the safety of Novartis AG’s experimental gene therapy drug … Novartis’ CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory PanelAJMC.com Managed Markets Network |
BU Today |
CReM Stem Cell Researcher Is Innovator of the Year
BU Today Those who know ancient history—the first decade of the 21st century—recall that embryonic stem cell research was a combustible issue, with supporters cheering the potential to create new tissues from stem cells and opponents decrying the destruction … |